A Phase 1 interventional study of MEDI0618 and Placebo in Chronic Pain, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-05.
Sponsored by AstraZeneca · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Chronic Pain with a site in Germany — 11 open to participants now, 14 under way, 8 of them phase 3. Chronic Pain · Germany.
Among the 70 studies in Chronic Pain with a site in Germany, this one is the 42nd largest by enrollment of the 50 interventional ones that give a count, is one of 6 that started in 2022, is one of 4 in phase 1, and was the 57th registered.
3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.
Browse Chronic Pain studies →11 of the 70 studies in Chronic Pain with a site in Germany are open now. Recruiting first, the newest first:
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 17 · Phase 4 2
First in 2003; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 91 across the 50 interventional studies, 167 across the 20 observational. Of the 54 that completed or were terminated, 21 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 70 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 6 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
1 of the studies in Chronic Pain with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06784141Prof. Dr. Julia GlombiewskiNetwork-Based vs. Standardized Cognitive Behavioral Therapy in Chronic Primary Pain | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies in Chronic Pain with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a single centre, randomised, double-blind, placebo-controlled, multiple ascending dose study of MEDI0618 in healthy male and female volunteers.
Subjects will receive MEDI0618 or placebo administered by intravenous infusion or subcutaneous injection.
Safety, tolerability and pharmacokinetics of multiple ascending doses of MEDI0618 will be assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A human immunoglobulin antibody to the Protease Activated Receptor 2 (PAR2)
Drug: MEDI0618
Histidine/histidine HCl, sucrose and polysorbate
Drug: Placebo
Four doses of 100 mg IV, 200 mg IV or 200 mg SC MEDI0618 administered once every two weeks.
Also known as: Protease-Activated Receptor 2 Antagonist
Four doses of IV placebo or SC placebo administered once every two weeks.
Incidence of adverse events
To characterise the safety and tolerability of MEDI0618 administered IV or SC
Time frame: From Screening, Day 1 to Day 113
Incidence of abnormal vital signs
To characterise the safety and tolerability of MEDI0618 administered IV or SC
Time frame: From Screening, Day 1 to Day 113
Incidence of abnormal laboratory parameters
To characterise the safety and tolerability of MEDI0618 administered IV or SC
Time frame: Day -1, Day 15, Day 29, Day 43, Day 57, Day 71, Day 99, Day 113
Time to maximum observed plasma concentration (Tmax) of MEDI0618
To characterise the pharmacokinetic (PK) profile of MEDI0618 administered IV or SC
Time frame: Day 1 to Day 113
Maximum observed plasma concentration (Cmax) of MEDI0618
To characterise the pharmacokinetic (PK) profile of MEDI0618 administered IV or SC
Time frame: Day 1 to Day 113
Area under plasma concentration-time curve over dosing interval (AUC[tau]) of MEDI0618
To characterise the pharmacokinetic (PK) profile of MEDI0618 administered IV or SC
Time frame: Day 1 to Day 113
Pre-dose trough concentration (Ctrough) of MEDI0618
To characterise the pharmacokinetic (PK) profile of MEDI0618 administered IV or SC
Time frame: Day 1 to Day 113
The volume of plasma cleared of drug per unit time (CL) of MEDI0618
To characterise the pharmacokinetic (PK) profile of MEDI0618 administered IV or SC
Time frame: Day 1 to Day 113
Anti-drug antibodies (ADA)
To characterise the immunogenicity of MEDI0618 administered IV or SC
Time frame: Day 1, Day 8, Day 29, Day 43, Day 57, Day 71, Day 99, Day 113
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2022 to primary completion in Dec 2023, 12 months.
Of 27 industry-sponsored phase 1 interventional studies under Chronic Pain, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 12 months is above that.
Counting every sponsor, half of 60 studies reached it within 12 months; a quarter within 6 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MEDI0618